ResMed, a medical device company focused on sleep apnea, has launched its first consumer product, a $149 device for tracking and improving sleep called S+. The platform includes a non-contact, ...

Two digital health companies focused on sleep published data this week that highlighted the efficacy of their respective platforms, bringing continued attention to the space after a CES week where ...

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea. The NightOwl testing device, about the size of a quarter, is worn on the user ...

ResMed, a leader in digital health with over 22.5 million cloud-connected devices sold, excels in treating respiratory disorders like sleep apnea, impacting over 1 billion globally. Recent data from ...

ResMed's fifth annual Global Sleep Survey highlights a significant global sleep crisis, revealing that 71% of employed individuals have called in sick at least once due to poor sleep, with the average ...

ResMed (NYSE:RMD) supports global respiratory care as s&p 500 chart discussions frame large healthcare organizations.

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ...